Anti-IL20
:Inflammation
:Phase 1
Novo Nordisk is developing anti-IL20, a monoclonal antibody neutralising the interleukin 20 protein. The clinical trial programme involves patients with moderate-to-severe plaque psoriases and rheumatoid arthritis.
- Company announcements
- No company announcements matching the search criteria
- Press releases
- No press releases matching the search criteria
- Scientific abstracts
- Accreditation and Quality Assurance (2002)
- Accreditation and Quality Assurance (2003)
- Accreditation and Quality Assurance (2005)
- Read more scientific abstracts
